Abstract
Background Gastrointestinal (GI) cancer patients face a 4-fold higher risk of suicide than the general US population. While efforts to reduce suicide risk in cancer patients have been crucial, the issue remains urgent. This study explores the psychosocial aspects of gastrointestinal (GI) cancer patient experiences. It focuses on assessing the prevalence and intensity of suicidal ideation and behavior, evaluating mental distress during different treatment phases, and examining the impact of psychosocial factors on mental health.
Method We used a two-phase mixed-methods approach. The research began with a web-based survey targeting individuals across the US who were undergoing or had completed GI cancer treatment. Survey respondents were then debriefed and invited to engage in a follow-up interview, which were conducted via video conferencing, recorded, transcribed, and anonymized for analysis. Quantitative data analysis involved confirmatory factor analysis to validate constructs related to mental health and suicidal ideation. Subsequently, significant correlations with mental health and suicidal ideation were extracted and scaled for further bivariate analyses. Qualitatively, an inductive thematic analysis was performed on both survey responses and interview transcripts. The patient journey was charted from diagnosis through the treatment continuum, with sentiment analysis enriching the thematic findings.
Results Two hundred-two individuals responded to the survey. Of all the participants, 76 respondents were from the rural Appalachian region, and 78 were undergoing treatment during the study. Quantitative analysis revealed a higher prevalence of passive suicidal ideation compared to active planning. The post-treatment recovery period was reported as the most emotionally challenging. Qualitative data emphasized the crucial role of emotional support, with patients feeling particularly vulnerable to isolation. The quality of care received was another concern, with calls for more individualized treatment plans and better communication. Patients also expressed a need for clear, comprehensive information about their treatment and potential side effects. The in-depth interview with 4 GI cancer patients indicated a healthcare system that prioritizes expedient treatment over comprehensive care, with a noted lack of formal psychological support. The role of artificial intelligence (AI) emerged as a promising avenue for enhancing patient understanding of their condition and treatment options. Patients valued clear, empathetic communication and the provision of comprehensive, understandable information from their healthcare providers. The sentiment analysis associated with their experiences reflected a spectrum of emotional responses, from shock and disbelief at diagnosis to fluctuating emotions during treatment.
Conclusion Our research advocates for a more patient-centric model of care, enhanced by the thoughtful integration of technology and consistent, empathetic communication. These findings contribute to a deeper understanding of the GI cancer patient experience and provide a foundation for improving cancer care practices to better address the holistic needs of patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ourstudy received ethical approval from the West Virginia University Institutional Review Board under protocol number 2212691613. The study qualified for the WVU Flexibility Review Model, as it involves minimal risk and adheres to the Belmont Report's ethical principles. Approval was granted on February 7, 2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors